Clinical trial NCT06798844: Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease
Official title: Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Freezing of Gait
Parkinson Disease
Keywords: Spinal Cord Stimulation
Freezing of Gait
Parkinson disease
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2025-01-29
Enrollment: 29
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Sham-controlled randomized double-blinded cross-over study
Primary purpose: TREATMENT

Brief summary: Freezing of gait (FOG) is a severely disabling gait disorder in Parkinson's disease (PD). Its poor response to current therapies reflects the shortfall in current knowledge on its exact pathophysiology. Case series suggest a therapeutic promise of spinal cord stimulation (SCS) for FOG, but double-blind randomised controlled trials with reliable FOG assessments are lacking.

This randomised, double-blind, placebo-controlled cross-over trial aims to define the outcome, safety, optimal stimulation paradigm and underlying mechanism of SCS for FOG in PD, by exploring both clinical and neurophysiological parameters.

Twenty-nine PD patients with refractory FOG will receive an implanted SCS lead connected to an external trial stimulator. During a 3-week trial, 3 stimulation paradigms will be tested in random order, including one sham paradigm. SCS outcome on FOG will be evaluated through wearable accelerometers, self-reported questionnaires and a FOG-provoking protocol at home. Spinal electrophysiological recordings will compare neural properties between PD patients with and without FOG and evaluate intra-patient differences (e.g., on/off medication, DBS states). In patients with deep brain stimulation (DBS) including BrainSense technology, the effect of SCS on pathological beta oscillations in the STN will be explored. A subsequent long-term open-label phase will be conducted in those patients who desire a definitive implanted stimulator.

This project will provide new insights into the pathophysiology of FOG, pave the way for SCS implementation in clinical practice and enhance future patient selection.

Detailed description: Freezing of gait (FOG) is a severely disabling gait disorder in Parkinson's disease (PD). FOG leads to falls, anxiety and loss of independence and heavily affects quality of life (QoL). The incidence of FOG increases from 38% in the first 5 years following diagnosis to 65-80% in advanced stages. FOG is a therapeutic challenge, as it often responds poorly to (dopaminergic) pharmacotherapy or deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal pallidum. Likewise, rehabilitation strategies such as gait training achieve small and short term effects at best. The therapeutic response of FOG is far more complex and variable than that of other PD motor symptoms. This reflects the current shortfall in knowledge about FOG pathophysiology, which has drastically impeded adequate therapy development. Furthermore, objective and reliable FOG assessments are challenging and therefore still rarely implemented in clinical trials, limiting the interpretation of the findings. However, recent insight into the underlying mechanisms has resulted in a growing body of literature suggesting a therapeutic promise of spinal cord stimulation (SCS) for FOG.

Spinal cord stimulation is an invasive technique in which specific neuronal circuits are stimulated electrically through spinal epidural electrodes. The stimulation settings can be adjusted to achieve a therapeutic effect, often by eliciting paraesthesia. SCS has been applied mostly in patients with refractory neuropathic pain. Serendipitously, PD patients who underwent SCS to treat comorbid neuropathic pain also noticed a beneficial effect on FOG. This finding led to SCS being further investigated as a therapy for FOG, but despite the encouraging results in animal studies, studies in humans are limited to case reports and series with inconsistent results. Randomised, double-blinded, high-quality trials in large cohorts are much needed for translation to clinical use. Correct blinding in SCS studies was historically impeded by stimulation-induced paraesthesia. However, recent innovations in SCS devices now enable paraesthesia-free stimulation and spinal cord electrophysiology recordings, creating new opportunities for research and trial design.

In addition to the small sample sizes and lack of randomisation and blinding, currently published reports on SCS for FOG lack clear clinical phenotyping of freezing and many also fail to use objective, reliable FOG assessments. Moreover, much remains unknown about the effect of SCS on spinal cord and STN electrophysiology and about optimal stimulation paradigms.

This sham-controlled randomized double-blinded cross-over study aims to define the outcome, safety, optimal stimulation paradigm and underlying mechanism of SCS for FOG in PD patients. Twenty-nine patients will receive a 3-week SCS trial with an implanted lead connected to an external stimulator, during which two SCS paradigms (one with and one without paraesthesia) and a sham paradigm will be compared:

1. Tonic SCS (paraesthesia-eliciting)
2. DTM SCS (paraesthesia-free)
3. Sham SCS (stimulation off)

The three SCS paradigms will be evaluated for 5 days each in a randomised order, split by a 2-day wash-out. SCS outcome on FOG will be evaluated through a wearable accelerometer, questionnaires and a FOG-provoking protocol at home. During this FOG-provoking protocol, participants have to perform 4 different tasks:

1. Timed Up and Go test;
2. One minute of 360° turns in place, alternating the direction after each turn;
3. Bathroom task, where patients have to walk 2m, enter the toilet through the doorway, turn around there and return to the starting position;
4. Clearing the table, where patients need to set and clear the table with 2 plastic plates and cups. Starting and ending point is at 2m away from the table. During the task, they are also required to move the chairs in place.

The first two tasks will be executed twice, once while dual-tasking (serial-3 subtractions) and once without. Patients are allowed to use a walking aid if necessary to complete the protocol. Each FOG-protocol is conducted both in off-meds (≥ 12h withdrawal) and on-meds (±1h after intake) conditions. The entire protocol is videorecorded and annotated afterwards to determine percentage time frozen (%TF) and characterisation of FOG. During the FOG-protocol, the participant will wear 5 intertial measurement units to quantify gait parameters. In patients with DBS including BrainSense technology, we will explore the effect of SCS on pathological beta oscillations in the STN.

Upon completion of the core trial, participants who exhibit a clinically relevant improvement in freezing or gait will receive a permanent implanted neurostimulator and continue into the long-term open-label phase. In participants who do not perceive a clinically relevant FOG improvement from SCS during the core trial, the trial electrode is removed. Six months following either implantation of the permanent neurostimulator or removal of the trial electrode, long-term therapeutic efficacy and safety of SCS for FOG will be assessed and compared between patients who received permanent SCS and those who did not. In addition, electrophysiological recordings of the dorsal spinal cord will be conducted at the end of the external trial stimulation and at the 6-month follow-up. These electrophysiological signal characteristics will be compared to two control groups of patients who received an Inceptiv SCS system outside research settings for approved indications (one group without PD, one group with PD but without FOG).

To conclude, this study will provide new insights into the pathophysiology of FOG, pave the way for SCS implementation in clinical practice and enhance future patient selection.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of idiopathic PD in accordance with the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease
* Optimal medical or DBS management for FOG, as evaluated by a movement disorder neurologist and programming expert. Stable PD medication and/or DBS settings for ≥ 1 month prior to baseline assessment and no changes are expected for the next 8 weeks
* Self-reported FOG severity of ≥ 1 FOG episode per day, based on NFOG-Q items 1 and 2
* Presence of FOG during in-hospital clinical assessment consisting of 3 FOG-provoking tasks, in the on-medication state
* Able to walk 10 meters unassisted without a walking aid (use of a cane is allowed)
* Able to understand study requirements and provide consent
* Age 40-79 years inclusive

Exclusion Criteria:

* Presence of other severe neurological, psychiatric or other disorder that may impede assessment of outcomes
* Contra-indications to SCS surgery (e.g. epidural fibrosis, inability to safely discontinue anticoagulant drugs, allergy to implants, medically inoperable)
* Cognitive impairment (Montreal Cognitive Assessment (MOCA) \<19/30)
* Chronic (\>6m) severe (numeric rating scale \>5/10) back or leg pain, or FBSS, as the antalgic effect of SCS could cloud our interpretations for its effect on FOG
* Duodopa pump or apomorphine injections
* Fall frequency \>1x/day (this criterion comprises only 'actual falls', no 'near falls')
* Absence of FOG during preoperative at-home FOG-protocol, in on- or off-medication assessment
* Pregnancy, lactating or active pregnancy plans

Primary outcomes:
measure: FOG-provoking protocol
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
Secondary outcomes:
measure: Safety
timeFrame: 6 months
measure: FOG-provoking protocol
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: FOG-provoking protocol
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: Changes in home-based gait function
timeFrame: Core-trial: 3 weeks
measure: Patient Global Impression of Improvement (PGI-I)
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: Changes in daily patient-reported FOG severity, falls and near-falls
timeFrame: Core-trial: 3 weeks
measure: Change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III and part IV.6
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: Change in Numeric (Pain) Rating Scale (NRS)
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: Change in Medication Quantification Scale (MQS)
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: Patient satisfaction
timeFrame: Core-trial: 3 weeks
measure: Change in New Freezing of Gait Questionnaire (NFOG-Q)
timeFrame: 6 months
measure: Change in Characterizing Freezing of Gait questionnaire (C-FOG)
timeFrame: 6 months
measure: Change in Parkinson's Disease 39-Item Quality of Life Questionnaire (PDQ-39)
timeFrame: 6 months
measure: Change in Levodopa Equivalent Daily Dose (LEDD)
timeFrame: 6 months
measure: Change in Parkinson Anxiety Scale (PAS)
timeFrame: 6 months
measure: Change in Beck Depression Inventory (BDI)
timeFrame: 6 months
measure: Change in Rem Sleep Behaviour Disorder Screening Questionnaire (RBDSQ)
timeFrame: 6 months
measure: Change in SCales for Outcomes in PArkinson's disease - Autonomic Dysfunction (SCOPA-AUT)
timeFrame: 6 months
measure: Patient satisfaction
timeFrame: 6 months
Other outcomes:
measure: STN-LFP recordings
timeFrame: Core trial: day 7, 14 and 21 post-surgery. Long-term: at 6 months follow-up.
measure: Spinal electrophysiological recordings
timeFrame: at 3 weeks and at 6 months
Locations:
city: Leuven
country: Belgium
facility: University Hospitals Leuven
Study officials:
affiliation: Department of Neurosurgery, University Hospitals Leuven
name: Philippe De Vloo, MD, PhD, Prof.
role: PRINCIPAL_INVESTIGATOR
References: